Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study
Authors:
- Niharika SamalaNSNiharika Samala
- José González-GonzálezJGJosé González-González
- Robert A JendersRJRobert A Jenders
- Monika SarkarMSMonika Sarkar
- Raymundo Garcia RezaRRRaymundo Garcia Reza
- Fabian RodasFRFabian Rodas
- Mark KipnesMKMark Kipnes
- Heather G. HuddlestonHHHeather G. Huddleston
- Taufik MominTMTaufik Momin
- Farheen ShaikhFSFarheen Shaikh
- Deven ParmarDPDeven Parmar
Open Access
- 15 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
Abstract
Background and Aims: Polycystic ovary syndrome (PCOS) is the leading endocrine disorder in reproductive-age women. Metabolic dysfunction–associated steatotic liver disease (MASLD) is common in women with PCOS, but they are underrepresented in MASLD therapeutic trials. We evaluated the safety and efficacy of saroglitazar, a novel peroxisome proliferator–activated receptors α/γ agonist, for the treatment of hepatic steatosis in women with PCOS and MASLD. Methods: In this multicenter, randomized, double-blind, placebo-controlled phase 2A trial, 60 women (18–45 y) with PCOS and MASLD were randomized 1:1 to either saroglitazar 4 mg or placebo for 24 weeks. The primary endpoint was relative (percent) change in hepatic fat content, measured by MRI proton density fat fraction. Primary analysis was performed in the per-protocol population (saroglitazar: 25; placebo: 23). Results: Participants in the saroglitazar group showed a significant reduction in percent hepatic fat content at 24 weeks from baseline compared to placebo ([least squares mean±SE]: −14.81±5.52 vs. 1.96±5.75, p =0.041). When controlled for baseline HbA1c imbalance, the beneficial effect of saroglitazar was more pronounced ([least squares mean±SE]: −18.93±4.83 vs. 6.43±5.04, p p =0.025). Saroglitazar also significantly reduced aminotransferase levels, lipid parameters, and the FibroScan AST score. Adverse events were comparable between the groups, and none were serious. One pregnancy in the saroglitazar arm resulted in uneventful maternal and neonatal outcomes. Conclusions: In women with PCOS and MASLD, saroglitazar significantly improved hepatic steatosis, liver enzymes, lipid profile, and FibroScan AST score. These findings support further evaluation of saroglitazar in larger studies in women with PCOS.Keywords
This publication has 18 references indexed in Scilit:
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver diseaseHepatology, 2023
- Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled AnalysisClinical Gastroenterology and Hepatology, 2023
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewHepatology, 2023
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 TrialHepatology, 2021
- Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-AnalysisClinical Gastroenterology and Hepatology, 2020
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation studyThe Lancet Gastroenterology & Hepatology, 2020
- Criteria, prevalence, and phenotypes of polycystic ovary syndromeFertility and Sterility, 2016
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)Diabetes Technology & Therapeutics, 2014
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)Human Reproduction, 2004
- Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populationsFertility and Sterility, 1992